List of works - Ian Judson

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas.

scientific article published on 14 June 2016

A patient presenting with a perivascular epithelioid cell tumor in the broad ligament: a case report

scientific article

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

scientific article

A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.

scientific article

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial

scientific article

Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case report

scientific article

Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST

scientific article published on 13 March 2009

Advanced aggressive fibromatosis: Effective palliation with chemotherapy.

scientific article

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

scientific article

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

scientific article published on 13 November 2006

Chemotherapy in clear cell sarcoma.

scientific article

Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial

scientific article

Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature

scientific article

Differential sensitivity of liposarcoma subtypes to chemotherapy

scientific article

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

scientific article

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

scientific article

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

scientific article

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

scientific article published on July 2007

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

scientific article published on 24 August 2015

Guidelines for the management of soft tissue sarcomas

scientific article

Histone Deacetylase Inhibition Increases Levels of Choline Kinase α and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers ⬇️

scientific article published on December 22, 2011

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital

scientific article

How to decide whether to offer and use "nonstandard" therapies in patients with advanced sarcomas and gastrointestinal stromal tumors: global variations in clinical practice, assessment, and access to therapies in diseases with limited incidence and

scientific article

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

scientific article

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

scientific article published in August 2005

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

scientific article

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

scientific article published on 23 June 2009

Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread

scientific article

Monogenic and polygenic determinants of sarcoma risk: an international genetic study

scientific article

Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity

scientific article

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

scientific article

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

scientific article

Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience

scientific article

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article

Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis

scientific article

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.

scientific article

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

scientific article

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

scientific article

Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies

scientific article

Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma

scientific article

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Tria

article

Primary Adult Renal Ewing's Sarcoma: A Rare Entity

scientific article published on 26 May 2009

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

scientific article

Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib

scientific article published on 01 April 2020

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program

scientific article published on 4 December 2014

Role of expert centres in the management of sarcomas

scientific article

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

scientific article

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy

scientific article

Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study

scientific article published on 09 September 2020

Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations ⬇️

scientific article published on May 3, 2011

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointesti

scientific article published on 31 March 2017

The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities

scientific article published on 31 January 2017

Therapeutic Drug Monitoring of Imatinib—New Data Strengthen the Case ⬇️

scientific article published on August 17, 2012

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomi

scientific article published on 16 November 2015

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial

scientific article

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors

scientific article

UK Guidelines for the Management of Bone Sarcomas ⬇️

scientific article published on December 29, 2010

UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).

scientific article

UK guidelines for the management of bone sarcomas

scientific article

UK guidelines for the management of soft tissue sarcomas

scientific article

List of works by Ian Judson

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas.

A patient presenting with a perivascular epithelioid cell tumor in the broad ligament: a case report

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial

Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case report

Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST

Advanced aggressive fibromatosis: Effective palliation with chemotherapy.

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Chemotherapy in clear cell sarcoma.

Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial

Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature

Differential sensitivity of liposarcoma subtypes to chemotherapy

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

Guidelines for the management of soft tissue sarcomas

Histone Deacetylase Inhibition Increases Levels of Choline Kinase α and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers ⬇️

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital

How to decide whether to offer and use "nonstandard" therapies in patients with advanced sarcomas and gastrointestinal stromal tumors: global variations in clinical practice, assessment, and access to therapies in diseases with limited incidence and

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread

Monogenic and polygenic determinants of sarcoma risk: an international genetic study

Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies

Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Tria

Primary Adult Renal Ewing's Sarcoma: A Rare Entity

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program

Role of expert centres in the management of sarcomas

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy

Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study

Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations ⬇️

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointesti

The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities

Therapeutic Drug Monitoring of Imatinib—New Data Strengthen the Case ⬇️

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomi

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors

UK Guidelines for the Management of Bone Sarcomas ⬇️

UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).

UK guidelines for the management of bone sarcomas

UK guidelines for the management of soft tissue sarcomas